{"id":35056,"date":"2023-07-03T12:00:00","date_gmt":"2023-07-03T12:00:00","guid":{"rendered":"https:\/\/www.euforea.org\/news\/la-comorbidite-oubliee-de-lasthme\/"},"modified":"2023-07-03T12:00:00","modified_gmt":"2023-07-03T12:00:00","slug":"la-comorbidite-oubliee-de-lasthme","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/fr\/news\/la-comorbidite-oubliee-de-lasthme\/","title":{"rendered":"La comorbidit\u00e9 oubli\u00e9e de l\u2019asthme"},"content":{"rendered":"
\n
\n
\n

Co-auteurs :<\/strong> Pr Wytske Fokkens, Pr Vibeke Backer, Dr Diego Conti, Mme Elizabeth Van Staeyen, Pr Glenis Scadding, Pr Peter Hellings, Pr Leif Bjermer, Pr Milos Jesenak, Pr Zuzana Diamant, Pr Susanne Lau.<\/em><\/p>\n

Un commentaire d\u2019EUFOREA faisant suite \u00e0 l\u2019article sur l\u2019\u00c9pid\u00e9miologie des comorbidit\u00e9s et leur association avec le contr\u00f4le de l\u2019asthme<\/a> refl\u00e9tant la collecte de donn\u00e9es aupr\u00e8s de plus de 12\u202f000 patients asthmatiques en Hongrie sur leur \u00e9tat, convaincu de l\u2019importance de r\u00e9pertorier la rhinosinusite chronique (RSC) avec ou sans polypes nasaux (RSCaPN ou RSCsPN) en raison de sa forte incidence et pr\u00e9valence, ainsi que de son association avec l\u2019asthme, laquelle est \u00e9galement approuv\u00e9e par la GINA et l\u2019EPOS. <\/p>\n

La RSC est une maladie r\u00e9pandue constituant un probl\u00e8me de sant\u00e9 majeur qui touche jusqu\u2019\u00e0 10,9 % de la population mondiale, tandis que la RSCaPN s\u00e9v\u00e8re est pr\u00e9sente chez environ 1 \u00e0 2 % de la population europ\u00e9enne. La pr\u00e9valence de l\u2019asthme chez les patients atteints de RSCsPN est de 21,2 %, et de 44,9 % pour les patients atteints de RSCaPN. Les deux entra\u00eenent une charge importante pour la soci\u00e9t\u00e9 en termes de consommation de soins de sant\u00e9 et de perte de productivit\u00e9. <\/p>\n

Lire l’article ici<\/strong><\/a><\/span><\/p>\n<\/div><\/div>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

Co-auteurs : Pr Wytske Fokkens, Pr Vibeke Backer, Dr Diego Conti, Mme Elizabeth Van Staeyen, Pr Glenis Scadding, Pr Peter Hellings, Pr Leif Bjermer, Pr Milos Jesenak, Pr Zuzana Diamant, Pr Susanne Lau. Un commentaire d\u2019EUFOREA faisant suite \u00e0 l\u2019article sur l\u2019\u00c9pid\u00e9miologie des comorbidit\u00e9s et leur association avec le contr\u00f4le de l\u2019asthme refl\u00e9tant la collecte de donn\u00e9es aupr\u00e8s de plus de 12\u202f000 patients asthmatiques en Hongrie sur leur \u00e9tat, convaincu de l\u2019importance de r\u00e9pertorier la rhinosinusite chronique (RSC) avec ou sans polypes nasaux (RSCaPN ou RSCsPN) en raison de sa forte incidence et pr\u00e9valence, ainsi que de son association avec l\u2019asthme, laquelle est \u00e9galement approuv\u00e9e par la GINA et l\u2019EPOS. La RSC est une maladie r\u00e9pandue constituant un probl\u00e8me de sant\u00e9 majeur qui touche jusqu\u2019\u00e0 10,9 % de la population mondiale, tandis que la RSCaPN s\u00e9v\u00e8re est pr\u00e9sente chez environ 1 \u00e0 2 % de la population europ\u00e9enne. La pr\u00e9valence de l\u2019asthme chez les patients atteints de RSCsPN est de 21,2 %, et de 44,9 % pour les patients atteints de RSCaPN. Les deux entra\u00eenent une charge importante pour la soci\u00e9t\u00e9 en termes de consommation de soins de sant\u00e9 et de perte de productivit\u00e9. Lire l’article ici<\/p>\n","protected":false},"author":1,"featured_media":35059,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[266],"tags":[172,174,194,224,284],"class_list":["post-35056","news","type-news","status-publish","has-post-thumbnail","hentry","category-publications","tag-asthme","tag-crswnp","tag-rhinosinusite-chronique-rsc","tag-polypes-nasaux-np","tag-publications"],"yoast_head":"\nLa comorbidit\u00e9 oubli\u00e9e de l\u2019asthme - EUFOREA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/news\/la-comorbidite-oubliee-de-lasthme\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La comorbidit\u00e9 oubli\u00e9e de l\u2019asthme\" \/>\n<meta property=\"og:description\" content=\"Co-auteurs : Pr Wytske Fokkens, Pr Vibeke Backer, Dr Diego Conti, Mme Elizabeth Van Staeyen, Pr Glenis Scadding, Pr Peter Hellings, Pr Leif Bjermer, Pr Milos Jesenak, Pr Zuzana Diamant, Pr Susanne Lau. Un commentaire d\u2019EUFOREA faisant suite \u00e0 l\u2019article sur l\u2019\u00c9pid\u00e9miologie des comorbidit\u00e9s et leur association avec le contr\u00f4le de l\u2019asthme refl\u00e9tant la collecte de donn\u00e9es aupr\u00e8s de plus de 12\u202f000 patients asthmatiques en Hongrie sur leur \u00e9tat, convaincu de l\u2019importance de r\u00e9pertorier la rhinosinusite chronique (RSC) avec ou sans polypes nasaux (RSCaPN ou RSCsPN) en raison de sa forte incidence et pr\u00e9valence, ainsi que de son association avec l\u2019asthme, laquelle est \u00e9galement approuv\u00e9e par la GINA et l\u2019EPOS. La RSC est une maladie r\u00e9pandue constituant un probl\u00e8me de sant\u00e9 majeur qui touche jusqu\u2019\u00e0 10,9 % de la population mondiale, tandis que la RSCaPN s\u00e9v\u00e8re est pr\u00e9sente chez environ 1 \u00e0 2 % de la population europ\u00e9enne. La pr\u00e9valence de l\u2019asthme chez les patients atteints de RSCsPN est de 21,2 %, et de 44,9 % pour les patients atteints de RSCaPN. Les deux entra\u00eenent une charge importante pour la soci\u00e9t\u00e9 en termes de consommation de soins de sant\u00e9 et de perte de productivit\u00e9. Lire l’article ici\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/news\/la-comorbidite-oubliee-de-lasthme\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/la-comorbidite-oubliee-de-lasthme\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/la-comorbidite-oubliee-de-lasthme\\\/\",\"name\":\"La comorbidit\u00e9 oubli\u00e9e de l\u2019asthme - EUFOREA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/la-comorbidite-oubliee-de-lasthme\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/la-comorbidite-oubliee-de-lasthme\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EUFOREA20comment20on20Lost20Comorbidity20of20Asthma20Paper20Teaser_0.png\",\"datePublished\":\"2023-07-03T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/la-comorbidite-oubliee-de-lasthme\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/news\\\/la-comorbidite-oubliee-de-lasthme\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/la-comorbidite-oubliee-de-lasthme\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EUFOREA20comment20on20Lost20Comorbidity20of20Asthma20Paper20Teaser_0.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/EUFOREA20comment20on20Lost20Comorbidity20of20Asthma20Paper20Teaser_0.png\",\"width\":1748,\"height\":1015},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/la-comorbidite-oubliee-de-lasthme\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/fr\\\/choisissez-votre-parcours\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"La comorbidit\u00e9 oubli\u00e9e de l\u2019asthme\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"La comorbidit\u00e9 oubli\u00e9e de l\u2019asthme - EUFOREA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/news\/la-comorbidite-oubliee-de-lasthme\/","og_locale":"fr_FR","og_type":"article","og_title":"La comorbidit\u00e9 oubli\u00e9e de l\u2019asthme","og_description":"Co-auteurs : Pr Wytske Fokkens, Pr Vibeke Backer, Dr Diego Conti, Mme Elizabeth Van Staeyen, Pr Glenis Scadding, Pr Peter Hellings, Pr Leif Bjermer, Pr Milos Jesenak, Pr Zuzana Diamant, Pr Susanne Lau. Un commentaire d\u2019EUFOREA faisant suite \u00e0 l\u2019article sur l\u2019\u00c9pid\u00e9miologie des comorbidit\u00e9s et leur association avec le contr\u00f4le de l\u2019asthme refl\u00e9tant la collecte de donn\u00e9es aupr\u00e8s de plus de 12\u202f000 patients asthmatiques en Hongrie sur leur \u00e9tat, convaincu de l\u2019importance de r\u00e9pertorier la rhinosinusite chronique (RSC) avec ou sans polypes nasaux (RSCaPN ou RSCsPN) en raison de sa forte incidence et pr\u00e9valence, ainsi que de son association avec l\u2019asthme, laquelle est \u00e9galement approuv\u00e9e par la GINA et l\u2019EPOS. La RSC est une maladie r\u00e9pandue constituant un probl\u00e8me de sant\u00e9 majeur qui touche jusqu\u2019\u00e0 10,9 % de la population mondiale, tandis que la RSCaPN s\u00e9v\u00e8re est pr\u00e9sente chez environ 1 \u00e0 2 % de la population europ\u00e9enne. La pr\u00e9valence de l\u2019asthme chez les patients atteints de RSCsPN est de 21,2 %, et de 44,9 % pour les patients atteints de RSCaPN. Les deux entra\u00eenent une charge importante pour la soci\u00e9t\u00e9 en termes de consommation de soins de sant\u00e9 et de perte de productivit\u00e9. Lire l’article ici","og_url":"https:\/\/www.euforea.org\/news\/la-comorbidite-oubliee-de-lasthme\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","twitter_card":"summary_large_image","twitter_site":"@euforea","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/news\/la-comorbidite-oubliee-de-lasthme\/","url":"https:\/\/www.euforea.org\/news\/la-comorbidite-oubliee-de-lasthme\/","name":"La comorbidit\u00e9 oubli\u00e9e de l\u2019asthme - EUFOREA","isPartOf":{"@id":"https:\/\/www.euforea.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/news\/la-comorbidite-oubliee-de-lasthme\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/news\/la-comorbidite-oubliee-de-lasthme\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EUFOREA20comment20on20Lost20Comorbidity20of20Asthma20Paper20Teaser_0.png","datePublished":"2023-07-03T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/news\/la-comorbidite-oubliee-de-lasthme\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/news\/la-comorbidite-oubliee-de-lasthme\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.euforea.org\/news\/la-comorbidite-oubliee-de-lasthme\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EUFOREA20comment20on20Lost20Comorbidity20of20Asthma20Paper20Teaser_0.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/EUFOREA20comment20on20Lost20Comorbidity20of20Asthma20Paper20Teaser_0.png","width":1748,"height":1015},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/news\/la-comorbidite-oubliee-de-lasthme\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.euforea.org\/fr\/choisissez-votre-parcours\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/news\/"},{"@type":"ListItem","position":3,"name":"La comorbidit\u00e9 oubli\u00e9e de l\u2019asthme"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/#website","url":"https:\/\/www.euforea.org\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.euforea.org\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news\/35056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/comments?post=35056"}],"version-history":[{"count":0,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/news\/35056\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/media\/35059"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/media?parent=35056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/categories?post=35056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/fr\/wp-json\/wp\/v2\/tags?post=35056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}